CC0000: The color(s) red (Pantone 187), yellow (Pantone 116) and a linear gradient blend thereof is/are claimed as a feature of the mark.
DM0000: The mark consists of the word "TRIGEN" next to a stylized oval, all above the words "ADVANCING CARDIOVASCULAR CARE".
GS0421: Scientific research for medical purposes; drug discovery and drug development services, consultancy services relating to the discovery, development and evaluation of drugs, technical support services, all provided by a pharmaceutical research and/or development company; research and development services to find and develop new pharmaceutical products for others to put on the market; pharmaceutical research services; pharmaceutical research services enabling others to acquire licences or other rights relating to the results or benefits, including candidate pharmaceutical products, arising from the research; arranging investigations and/or research to obtain information and/or data, to be supplied to others, relating to drugs, formulations and/or candidate pharmaceutical products; preparing or arranging the preparation of chemicals, biological products, formulations and/or candidate pharmaceutical products to enable others to acquire information, data and/or rights relating to the preparative techniques and/or prepared products; the provision of reports and information relating to chemicals, biological products, the preparation of either, formulations, candidate pharmaceutical products, pharmaceutical or medical research projects, pharmaceutical or medical research services, medicine, chemistry, molecular biology, disease and/property rights; the obtainment and compilation, for the benefit of others, of information, data and/or documents relating to candidate pharmaceutical products, enabling prospective business partners, licensees and/or assignees to assess the information, data and/or documents; acquiring or arranging the acquisition of intellectual property rights (including the preparation, filing and prosecution of patent applications), to enable others to licence-in or buy-in the rights; licensing of intellectual property rights; assigning intellectual property rights; provision on the Internet of documents and information relating to chemicals, biological molecules, the preparation of either, pharmaceutical agents, pharmaceutical formulations, candidate pharmaceutical products, pharmaceutical or medical research project, pharmaceutical or medical research services, chemistry, molecular biology, disease and/or intellectual property rights; scientific and pharmaceutical research services relating to blood clotting and/or thrombosis and to substances for use in controlling blood clotting or for the treatment or prevention of thrombosis; provision of information relating to research and development activities concerning blood clotting, thrombosis, and/or substances for use in controlling blood clotting or for the treatment or prevention of thrombosis
Case File Event Statements
12/8/2009 - 15 years ago
22 - ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDType:MAB2
12/8/2009 - 15 years ago
21 - ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEType:ABN2
5/12/2009 - 15 years ago
20 - NOTIFICATION OF NON-FINAL ACTION E-MAILEDType:GNRN
5/12/2009 - 15 years ago
19 - NON-FINAL ACTION E-MAILEDType:GNRT
5/12/2009 - 15 years ago
18 - NON-FINAL ACTION WRITTENType:CNRT
4/21/2009 - 15 years ago
17 - LIE CHECKED SUSP - TO ATTY FOR ACTIONType:RCCK
4/21/2009 - 15 years ago
16 - ASSIGNED TO LIEType:ALIE
10/17/2008 - 16 years ago
15 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDEDType:RCSC
10/17/2008 - 16 years ago
14 - ASSIGNED TO LIEType:ALIE
4/17/2008 - 16 years ago
13 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDEDType:RCSC
10/17/2007 - 17 years ago
12 - REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDEDType:RCSC
4/6/2007 - 17 years ago
11 - LETTER OF SUSPENSION E-MAILEDType:GNSL
4/6/2007 - 17 years ago
10 - SUSPENSION LETTER WRITTENType:CNSL
3/30/2007 - 17 years ago
9 - AMENDMENT FROM APPLICANT ENTEREDType:ACEC
2/23/2007 - 17 years ago
8 - CORRESPONDENCE RECEIVED IN LAW OFFICEType:CRFA